Jens Würthner has joined Netherlands-based Scenic Biotech BV as chief medical officer to help lead development of the company’s pipeline of genetic modifier-based small molecule drugs for metabolic diseases. Dr Würthner previously led clinical development at ADC Therapeutics SA, overseeing the development of Zynlonta, approved in 2021 for diffuse large B cell lymphoma. Prior to this he helped lead clinical development at Novartis.
Dr Würthner holds an MD and PhD from the University of Hamburg in Germany and is a visiting professor at Kings College London in the Faculty of Life Sciences & Medicine.
Scenic Biotech announced the appointment on 24 October 2022.
Copyright 2022 Evernow Publishing Ltd